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ABSTRACT
Steroid hormone receptors require the ordered assembly of various chaperone and
cochaperone proteins in order to reach a functional state. The final stage in the receptor
maturation process requires the formation of a mutimeric complex consisting of Hsp90
dimer, p23, and one of several large immunophilins. Studies conducted previously
demonstrated that the large immunophilin FKBP52 acts to potentiate glucocorticoid,
androgen, and progesterone receptor signaling pathways. The aim of these studies was
to identify and characterize FKBP52-specific inhibitors that would not only serve as tools
for the pharmacological analysis of FKBP52-receptor interactions, but may also lead to
novel drugs with significant therapeutic potential. A modified receptor-mediated reporter
assay in yeast used to screen a natural compound library for FKBP52 inhibitors led to
the identification of multiple hits. Structure activity relationship studies using the yeastbased assays led to the characterization of fifteen additional inhibitors, some of which
display dramatically increased potency. Surface plasmon resonance studies confirmed
that these inhibitors disrupt FKBP52 function through interaction with the AR hormone
binding domain. In addition, scintillation proximity binding and fluorescence polarization
assays demonstrated that the compounds bind to a previously unrecognized regulatory
surface domain on the AR LBD termed BF3. Interestingly, mutations within the BF3
surface lead to increased dependence on FKBP52 for normal function. ELISA and
Western immunoblotting analysis in prostate cancer cells demonstrated that the
compounds inhibit Prostate-Specific Antigen and FKBP51 expression. In addition,
androgen-dependent cell proliferation was prevented after treatment with the inhibitory
vii

molecules. In summary we have identified molecules that inhibit FKBP52 regulation of
AR function and represent an exciting new approach for the treatment of prostate
cancer. In addition, these studies provide new insight into FKBP52-AR structural and
functional interactions.
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CHAPTER 1
INTRODUCTION

I.

Androgen Receptor Function
Nuclear receptors are proteins responsible for sensing the presence of hormones

and other molecules. In response to hormone, these receptors regulate the expression
of specific genes in order to control cell development, homeostasis, and metabolism [1].
The androgen receptor is a nuclear receptor [2] that is activated by the binding of the
androgenic hormone testosterone and its derivatives [3]. Androgen-regulated genes are
critical for the development and maintenance of the male sexual phenotype [4, 5].
Figure 1.1 shows a model of nuclear steroid hormone receptor function were the ligand
binds the receptor, chaperone proteins disassociate, and the activated receptor dimer
enters the nucleus and interacts with DNA to mediate changes in gene expression [6].
The androgen receptor dimer binds to a specific DNA sequence known as a hormone
response element. Androgen receptors interact with additional proteins in the nucleus
resulting in “up” or “down-regulation” of specific gene transcription [6]. Up-regulation or
activation of transcription results in the increased synthesis of messenger RNA, which in
turn is translated by ribosomes to produce specific proteins.

1

Figure 1.1. Androgen Receptor Action.
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Figure 1.1. Androgen Receptor Action. Circulating testosterone enters prostate cells
and is converted into dihydrotestosterone (DHT). When activated by the binding of the
hormone ligand, the androgen receptor (AR) dissociates from chaperone proteins and
becomes phosphorylated. AR dimerizes, translocate into the nucleus and binds directly
to DNA at the androgen-response elements (ARE) in the promoter regions of the target
genes. Activation or repression of the target genes control biological responses such as
cell growth, proliferation, homeostasis, metabolism and prostate-specific antigen
secretion (PSA).
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II.

Model of Chaperone-Mediated Steroid Hormone Receptor Assembly
Steroid hormone receptors are ligand-dependent transcription factors. In the

absence of hormone the receptors exist in the cytoplasm and/or the nucleus complexed
with heat shock protein 90 (Hsp90) and other cochaperones. Upon hormone binding the
receptor-Hsp90 complex dissociates and the receptors dimerize in the nucleus where
they bind to hormone response elements enhancing the expression of a wide variety of
genes. The interests in our laboratory focus on chaperone proteins that bind to and
regulate steroid hormone receptors. At least ten chaperone and cochaperone proteins
are required for normal receptor function, including Hsp70 and Hsp90. All of these
factors offer the potential opportunity for therapeutic intervention. We are interested in
understanding the manner in which these factors influence receptor folding, hormone
binding, nuclear translocation, dimerization, and DNA binding. Work conducted
previously demonstrated that the maturation of the steroid hormone receptors to the
mature hormone binding confirmation is a highly ordered, dynamic process that involves
at least ten chaperone and cochaperone components, all of which present an
opportunity for therapeutic intervention. The steroid receptor folding pathway depicted in
Figure 1.2 has been thoroughly reviewed [7, 8] and is briefly described here.
Much of the knowledge of steroid hormone receptor folding has been gleaned
from in vitro receptor assembly assays for progesterone receptor (PR) [9-14] and
glucocorticoid receptor (GR) [15], but the process is likely to be similar for other steroid
receptors given that their associated chaperone complexes are nearly identical.

4

Unfortunately, these assays reveal nothing about early nascent chain folding. Thus, our
knowledge of the steroid hormone receptor folding process is restricted to folding events
subsequent to nascent chain folding. However, it is thought that the receptors associate
with Hsp70 and its cochaperone, Hsp40, early in the folding process, possibly even as
the receptor is being translated on the ribosome [16]. The Hsp70 complex is not only
thought to aid in the early folding process, but is a prerequisite for receptor association
with the Hsp90 complex. After association with the receptor, the Hsp70 complex recruits
the Hsp interacting protein (Hip), Hsp organizing protein (Hop), and Hsp90. Hop acts as
a scaffolding protein to bridge the Hsp70 and Hsp90 complexes by way of its multiple
tetratricopeptide repeat domains. Following Hsp90 association a rearrangement occurs
in which the interaction with Hsp70 is lost and the p23 cochaperone and one of several
immunophilin proteins are recruited to the receptor-Hsp90 complex. It is this form of the
complex that the receptor is capable of high affinity hormone binding. In the case of PR
the mature conformation of the receptor lasts only several minutes [17], which
correlates with the slow ATPase cycle of Hsp90 [18-22]. After several minutes the
complex dissociates and the receptor is recycled back into the chaperoning pathway.
Thus, the receptor-folding pathway is a dynamic, ordered process that involves many
transient interactions. In the absence of Hsp90 the receptors are unstable and degraded
rapidly through the proteosomal degradation pathway.
Given that chaperone interactions with the receptors are restricted to the ligand
binding domains (LBD), it is generally thought that the chaperones assist the LBD in
achieving and maintaining the high affinity hormone binding conformation through the
classic “folding and holding” chaperone role. However, it is also clear that some of the
5

chaperone components have a direct regulatory role in the receptor signaling pathways.
The Hsp90 complex effectively silences steroid hormone receptor function until
hormone binding occurs by blocking access to the receptor nuclear localization signal,
receptor dimerization, and the association of transcriptional coactivators [reviewed in
23]. Additionally, evidence suggests that the large FK506 binding protein (FKBP)
immunophilin FKBP52 can directly influence receptor hormone binding [24-26] and
consequently its function.

6

Figure 1.2. Chaperone-Mediated Receptor Folding Pathway.
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Figure 1.2. Chaperone-Mediated Receptor Folding Pathway. The SHR maturation
process involves the interaction with chaperone and co-chaperone proteins and an
immunophilin protein in the last step. After this dynamic process the receptor is in a
mature hormone-binding conformation.
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III.

Steroid Hormone Receptor-Associated Immunophilins
The immunophilins comprise several protein families including the FK506 binding

proteins (e.g. FKBP51 and FKBP52), cyclosporine A binding proteins (e.g. Cyp40), and
a protein phosphatase (e.g. PP5). Four immunophilins have been identified to associate
with steroid receptor-Hsp90 complexes, all of which are listed in the above examples
[10, 27-32]. The Hsp90-binding immunophilins contain a single TPR domain
(Tetratricopeptide repeat), which comprises the Hsp90-binding domain. In addition, the
FKBPs and Cyp40 contain a peptidyl-prolyl isomerase (PPIase) domain and PP5
contains a protein phosphatase domain. Although all four of these TPR-containing
proteins compete for binding the Hsp90-steroid receptor complexes, only the
association of FKBP51 and FKBP52 with AR, GR or PR complexes appear to represent
relevant functional interactions [reviewed in 5].
Over expression of FKBP52 in the budding yeast S. cerevisiae and in various
mammlian cell culture systems potentiates AR, GR and PR-mediated expression of a
reporter gene up to 20-fold, however it has no effect on estrogen receptor (ER) and
mineralicorticoid receptor (MR) function [25, 26, 33]. Using FKBP52 mutants unable to
bind Hsp90 (K354A), display PPIase activity (FD67DV), or immunosuppressive ligands
that bind to and inhibit the PPIase enzymatic activity, Dr. Smith lab demonstrated that
FKBP52 potentiation of receptor function requires a functional PPIase domain and
interaction with Hsp90 (Fig. 4B). Studies conducted by the Smith lab and others suggest
that FKBP52 potentiation occurs through enhancement of receptor hormone binding
affinity [24, 26]. Domain swapping experiments between the various steroid receptors
9

demonstrated that FKBP52 potentiation localized to the receptor ligand binding domain
[25]. Thus, a plausible hypothesis is that the FKBP52 PPIase binds to and catalyzes the
isomerization of a relevant proline substrate in the receptor ligand binding domain,
thereby increasing the affinity for hormone. However, it is not the PPIase activity that is
required for potentiation, but the PPIase (also termed FK1) domain. The current
prevailing hypothesis is that the FKBP52 PPIase catalytic pocket is part of an interaction
surface and the interaction is disrupted by the immunosuppressive ligands, which
protrude out from the catalytic pocket. We do not know the identity of the interaction
partner, but evidence suggests that it is the steroid receptor ligand binding domain.
The physiological significance of the FKBP52 effects observed in cellular studies
has been confirmed in a mouse gene knockout model. Both male and female FKBP52
knockout (52KO) mice are infertile [26, 33]. The 52KO male mice display specific
reproductive phenotypes directly linked to defects in androgen receptor function. The
observed phenotypes are consistent with partial androgen receptor insensitivity
including ambiguous external genitalia, the presence of nipples that persist through
puberty, and dysgenesis of the prostate and seminal vesicles. The 52KO female mice
display defects in implantation and decidualization that are directly related to defects in
progesterone receptor function. Although the 52KO mice do not display any obvious
phenotypes related to defects in GR function, we have observed a 3-fold higher level of
serum corticosterone in both the 52KO males and females as compared to their wild
type litter mates [34]. Thus, the 52KO mice are likely compensating for reduced GR
function.
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High resolution crystal structures have been solved for full-length FKBP51 [35]
and for overlapping fragments of FKBP52 [36, 37]. FKBP52 shares ~70% sequence
similarity and is structurally similar to FKBP51. Figure 1.3 indicates FKBP51 and
FKBP52 structural comparisons and domain organizations. In contrast to FKBP52,
FKBP51 overexpression in both yeast and mammalian cell assays has no effect on
receptor function alone. However, co-expression of FKBP51 and FKBP52 demonstrated
that FKBP51 acts to antagonize FKBP52-mediated potentiation of receptor function
[25]. It is likely that FKBP51 is doing more than simply competing with FKBP52 binding
with Hsp90 as the other steroid receptor-associated immunophilins do not antagonize
FKBP52 potentiation. Thus, we believe that FKBP51-mediated antangonism of FKBP52
potentiation is functionally relevant for steroid hormone receptor regulation. In a
physiological setting, FKBP51 expression is induced by glucocorticoids, progesterone
and androgens [38-44]. Thus, the hormone-induced expression of FKBP51 may
represent a negative feedback loop. Although we have not observed any obvious
phenotypes in the FKBP51 knockout mice (51KO), this negative feedback loop may be
important under specific physiological conditions. In addition, the loss of both FKBP51
and FKBP52 in mice results in an embryonic lethal phenotype [34]. Thus, FKBP51 and
FKBP52 clearly have some redundant developmental functions. Finally, some of the
strongest physiological evidence for a relevant role of FKBP51 in steroid receptor
regulation comes from studies in New World primates. Cortisol resistance in New World
primates has been attributed to FKBP51 [45, 46]. In conjunction with collaborators from
Smith lab that demonstrated squirrel monkey FKBP51 displays a higher basal level of

11

expression and a more robust inhibition of GR ligand pontency as compared to human
FKBP51 [47].

12

Figure 1.3. Receptor-Associated Immunophilins.
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Figure 1.3. Receptor-Associated Immunophilins. A common feature shared by
Immunophilin proteins is the presence of the TPR motif and additional functional
domains. The TPR domain helps in protein-protein interactions and is responsible for
Hsp90 binding. Two members of the FKBP family which possess Hsp90 binding abilities
are FKBP51 and FKBP52. In FKBP51, the TPR domain projects at an angle from the
rest of the protein, but in FKBP52 the TPR domain is more extended in comparison with
the rest of the protein. FKBP51, FKBP52 and Cyp40 have the ability to bind
immusuppressive drugs by their PPIase domains. Cyclophilins (CyP) bind the drug
cyclosporine-A while the FKBP’s bind the immune suppressant FK506. In both FKBP51
and FKBP52, the FK1 domain has functional PPIase activity, while the FK2 domain is a
PPIase like domain with unknown function. FK1 regions are conserved between these
proteins, with the exception of a few amino acids at the edge of the PPIase domain. The
FK loop is the hinge region that connects FK1 to FK2. FKBP51 exhibits ionic bonding
between the FK2 and TPR domains, whereas FKBP52 lacks these bonding abilities and
is therefore more flexible in nature. FKBP51 and FKBP52 are 60% identical and
approximately 70% similar in amino acid conservation.
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IV.

Prostate Cancer

According to the National Cancer Institute (NCI) prostate cancer is the major leading
cause of death in males in the United Sates. There have been 217,730 new cases of
prostate cancer and 32,050 deaths from prostate cancer in 2010. In addition, data from
previous years indicate that 16.22% of males born today (1 in 6 males) in the United
States will be diagnosed with prostate cancer at some point during their lifetime. These
lifetimes risk statistics are available at the NCI website
(http://seer.cancer.gov/statfacts/html/prost.html). Prostate cancer (PCa) occurs when
cells within the prostate grow uncontrollably, creating small tumors [44, 48]. Prostate
cancer growth is dependent on androgens and the androgen receptor function of
regulating gene expression [48-50].
Several mechanisms of action for prostate cancer development have been reported
[51-53] (figure 1.4). The first mechanism requires the presence of androgens to activate
AR, followed by receptor translocation to the nucleus. The second mechanism results
from amplification of AR that is activated in the absence of hormone or mutations in the
receptor that make it capable of activation by either cytokines or growth factors. This
later model suggest prostate cancer cell growth and tumor formation independent of the
presence of hormones. Subsequent up-regulation of genes that promote cell growth and
proliferation would result in tumor formation in the prostate. In the later mechanism, AR
action is bypassed and an overexpression of Bcl-2 leads to the activation of genes that
cause the formation of tumors within the prostate [52].

15

Figure 1.4. Prostate Cancer Development Mechanisms.
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Figure 1.4. Prostate Cancer Development Mechanisms. The androgen-dependent
mechanism requires the presence of androgenic hormone to activate the Androgen
Receptor (AR) which leads to up regulation of genes that promote cell growth and
subsequent cell proliferation and tumor formation. In the androgen-independent
mechanism there is amplification of AR that is activated by additional molecules that are
not typically androgenic hormones. This second mechanism describes prostate cancer
cell growth and tumor formation independent of the presence of hormones.
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The prostate is an androgen-dependent tissue that requires adequate AR activity
for its development and maintenance. Dihydrotestosterone (DHT) is the primary ligand
for AR in prostate tissue and it is synthesized from testosterone by reductase enzymes.
As previously mentioned, during the AR maturation process the receptor interacts with
cochaperone proteins, such as FKBP52, in order to induce high affinity androgen
binding and to promote AR translocation to the nucleus [49]. The effect of AR in the
transcriptional machinery of the cell is crucial for prostate cancer development since
androgens promote cell growth, proliferation and survival [54-56] and are a major
stimulator of tumor progression [57]. Therefore, under abnormal conditions, AR
hyperactivity can contribute to the development of prostate cancer [58].
During early stage prostate cancer (EPc), the cancer progress is totally
dependent on androgen accessibility. This requirement is the basis for the frequently
used androgen ablation therapies that repress AR function by means of blocking the
action of androgens by decreasing their levels in circulation or by competing for receptor
binding. As a result cell growth and proliferation is prevented, AR-target genes’
expression is reduced and tumor progression is repressed, making this therapy a
principal option to be used for the treatment of EPc [48, 55, 59, 60]. However,
androgen-resistant prostate cancer can reoccur and maintain a dependency on AR
activity for growth and proliferation. This state is referred to as androgen independent,
ablation resistant, or late stage PCa [61, 62]. Large scale gene-profiling studies have
shown that late stage prostate cancer cells and tumors continue to express AR and
secrete prostate specific antigen (PSA) like early stage prostate cancer cells [48, 49,
61]. These results indicate that AR remains important for androgen-independent
18

prostate cancer development and AR-regulated gene expression contribute to late
stage PCa cell growth and progression [33, 44, 50, 63-65]. This phenomenon can be
attributed to mutations in AR that make it reactive in the absence of DHT and cause
oncogenic transformation of the prostate, impaired function of AR regulators, or
changes in the signal transduction pathways that regulate AR activity [49]. At this point
of prostate cancer progression the receptor might have the ability to be activated by
molecules other than its primary ligand [48], thus new strategies to target AR activity are
needed.
Co-regulators of the androgen receptor are beginning to be acknowledged as
possible candidates for the treatment of these hormone-related and hormone-resistance
diseases. The immunophilin protein FKBP52 is expressed in prostate tissue from
prostatic hyperplasia patients [66] and interacts with the androgen receptor in prostate
cancer cells [67] suggesting that it has a vital role in AR-mediated PCa cell growth and
gene transcription. MALDI-TOF MS/MS studies of prostate needle biopsies [61]
confirmed that FKBP52 is up-regulated in prostate cancer cell lines as compared to
normal prostate cells, [67, 68] suggesting that this immunophilin is involved in AR
activity in these tissues. As mentioned previously, FKBP52 has a positive physiological
role in up-regulating AR activity, not only by interacting with AR-chaperone complexes,
but also by potentiating receptor function [33, 55, 69] and enhancing AR-dependent
transcription [33, 70]. In addition, studies of FKBP52 knockout mice have shown that
this protein is essential for AR activity in the prostate [33, 71]. Therefore it has been
postulated that AR positive regulators can be selectively targeted to achieve inhibition of
AR-induced cell proliferation of PCa cells.
19

An alternative treatment for late stage PCa might be the inhibition of AR
activation mechanisms, such as altering the interactions with chaperone proteins during
the AR maturation process. AR mutations commonly found in late stage prostate
cancer patients are positioned within our putative FKBP52 interaction surface on the
androgen receptor. Previous studies from Dr. Cox’s laboratory have shown that these
mutations result in a mutant AR that displays increased dependence on FKBP52 for
normal function [34]. Over-expression of FKBP52 positively affects the hormoneindependent activity and basal signaling of mutated AR (L710H) in yeast models and
stimulates hormone-independent signaling of AR (L710H) in PCa cells [72] suggesting
that FKBP52 can bind AR and have chaperone function in prostate cancer cells.
Therefore, targeting proteins involved in AR activation pathways that physically interact
with AR, such as FKBP52, can inhibit androgen-induced cell growth and gene
transcription in PCa cells by preventing hormone binding to the receptor and/or receptor
translocation to the nucleus. Based on these observations we assume that in early and
late stage PCa, AR is still dependent on molecular chaperones for its functional
properties, FKBP52 cochaperone can increase AR activity and FKBP52 inhibitors will
prevent AR regulation of PCa growth and progression.
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V.

Dissertation Goal

The maturation of steroid receptors to the final hormone binding conformation is a
process that involves several chaperone proteins, all of which present an opportunity for
therapeutic intervention into prostate cancer. HSP90 binds to immunophilin proteins
(FKBP52) for subsequent interactions with steroid receptors, kinases, and other cellular
signaling factors that play important physiological and potentially pathological roles in
mammals. The inhibition of FKBP52 represents an attractive therapeutic option for the
treatment of diseases that are dependent upon a functional hormone signaling pathway.
Gaining a better understanding of the mechanism by which FKBP52 regulates receptor
function and of the molecular determinants of FKBP52 specificity, will support
downstream efforts in the therapeutic targeting of Hsp90 client proteins with a high
degree of specificity. FKBP52-specific drugs could potentially have an advantage over
the Hsp90 inhibitors that are currently being tested in clinical trials for the treatment of
various cancers and endocrine diseases since FKBP52 is more selective for Hsp90
client proteins. Thus, FKBP52 inhibitors should be less toxic as compared to Hsp90
inhibitors.
The ability of steroid receptors to activate pathways defined as key regulators of cell
growth is likely to play an important role in the development of resistance to endocrine
therapies [73]. The goal of these studies is to develop novel small molecule inhibitors of
FKBP52 that can be used to treat hormone-dependent diseases such as prostate
cancer, benign prostatic hypertrophy, diabetes and obesity. In addition theses small
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molecules could potentially be used as male contraceptives and research reagents for
the study of androgen receptor interactions and their function.
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CHAPTER 2
IDENTIFICATION OF MOLECULES THAT SPECIFICALLY INHIBIT FKBP52ENHANCED RECEPTOR FUNCTION

I.

Rationale
Previous studies have established FKBP52 as an important positive regulator of

steroid hormone receptor function. Biochemical and cellular studies suggest that
FKBP52 directly contacts the receptor hormone binding domain within the receptorHsp90 complex, which ultimately results in increased hormone binding to the receptor.
The studies detailed herein were in part conducted in order to better understand
FKBP52-receptor interactions. In addition, the steroid hormone receptor-specific
phenotypes observed in the fkbp52-deficient mice have firmly established FKBP52 as
an attractive therapeutic target for the treatment of hormone-dependent diseases. Thus,
a small natural compound library screen in a yeast system was performed in order to
identify FKBP52-specific inhibitors that could serve as research tools for the study of
FKBP52-receptor interactions and as therapeutic candidates for the treatment of
disease. Previous experiments performed by Dr. Neckers’ laboratory at the National
Cancer Institute identified two initial compounds (H7 and H8) as possible FKBP52specific inhibitors. Using these original hits, we have acquired molecules that represent
slight structural modifications and then assessed them for their ability to prevent
FKBP52 potentiation of receptor activity.
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II.

Materials and Methods

Yeast Strains and Assays. β-galactosidase reporter assays developed previously
described [25, 74-76] were used as a quantitative indicator of hormone receptor activity
and for the yeast-based medium-throughput compound library screens. The basic
reporter strains used for wild type AR, indicated AR point mutant, and GR assays were
based on a W303a genetic background (MATa leu2-112ura3-1 trp1-1 his3-11, 15 ade21 can1-100 GAL SUC2) and all contained a URA3-marked steroid receptor-mediated βgalactosidase reporter plasmid (pUCΔs-26X, kind gift from Brian Freeman, University of
Illinois, Urbana-Champaign, IL). The parent plasmids for all other yeast expression
vectors were described previously [77]. The AR point mutants were generated directly in
the yeast expression vector by site-directed mutagenesis using the QuickChange kit
(Stratagene) according to the manufacturer’s instructions. For hormone-responsive
reporter assays, the indicated strains were co-transformed with the following three
plasmids: a hormone-inducible β-galactosidase reporter plasmid, a LEU2-marked highcopy number plasmid constitutively expressing the indicated steroid hormone receptor
from a glyceraldehyde phosphate dehydrogenase (GPD) promoter, and a TRP1-marked
high-copy number plasmid with or without human FKBP52 where indicated.
Transformants were selected and maintained on synthetic complete dextrose medium
lacking uracil, leucine, and tryptophan. All hormones were obtained from Sigma (St.
Louis, MO) and were stored as 10 mM stock solutions in ethanol. Hormone dilutions
were generated so that the ethanol vehicle never exceeded 1% total volume in the
yeast cultures. The hormone concentrations were optimized by performing doseresponse curves. Hormone-induced reporter activity was measured from yeast extracts
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as described previously [25] with a single two-hour time point measurement. All assays
were performed minimally in triplicate and data presented from at least three
independent experiments that produced consistent results.

Compound Library Screening. The yeast-based β-galactosidase reporter assays used
to screen the library of compounds were performed as previously described [78] with
modifications to a 96-well plate format (Figure 2.1). The strain and plasmids used for the
library screens were the same as those described above except the parent yeast strain
was deleted for the pleiotropic drug resistance 5 (PDR5) gene in order to avoid the
potential transport of candidate compounds out of the yeast. Two reporter strains were
used in the library screen. The control strain contained a wild type human AR
expression plasmid and an empty TRP1-marked plasmid, and the tester strain
contained an AR-P723S expression plasmid and a TRP1-marked human FKBP52
expression plasmid. The assay protocol was designed to identify compounds that
specifically reduce signaling from the tester strain and not the control strain (FKBP52specific inhibition). The use of the wild type AR control strain controlled for specificity
and general toxicity including effects on growth, transcription, translation and protein
stability. The AR-P723S point mutant was previously described as being hypersensitive
to FKBP52 potentiation [33]. The use of this mutant in these assays increased the
sensitivity of detection as signaling at the hormone doses used in the tester strain
depends entirely on the presence of FKBP52. Preliminary dose response curves were
performed and the DHT concentrations used in the library screening assays were based
on the EC50 values determined in both the control and tester strains. The Diversity Set
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Library available through the Developmental Therapeutics Program of the National
Cancer Institute was chosen for the screen. This library contains approximately 2000
identified compounds that were selected to have representative diverse chemical
structures derived from a collection of almost 140,000 compounds. For the screening
assays the cultures were grown in synthetic complete medium lacking uracil, leucine,
and tryptophan at 30.0 ˚C in a shaking water bath and the optical density at 600 nm
(O.D.600) was monitored until the cultures were in exponential phase growth (O.D.600 =
0.08 to 0.10). Cultures were then aliquoted into a 96-well plate at 100 μl per well and
compounds added. The compounds were stored in dimethyl sulfoxide (DMSO), while
yeast can tolerate up to 5% DMSO without significant effects on the assay results.
Thus, care was taken not to exceed the 5% DMSO limit. All library compounds were
assayed in the control and tester strains at a single concentration of 50 µM. Hormone
was added 1 hr after compound addition and at 2 hrs 100 ul of Tropix Gal-Screen
reagent (Applied Biosystems, Foster City, CA) was added to each well. The plates were
incubated for an additional1 hr and 30 min at room temperature and light emission
measured on a microplate luminometer (Luminoskan Ascent, Thermo Labsystems).
Two compounds were identified (H7 and H8) to inhibit FKBP52-enhanced receptor
function but did not affect AR function alone. These compounds were further analyzed
for effects in wild type AR and GR reporter assays as described above. An additional 28
compounds that represented slight structural modifications of H7 were design by
Johanny Tonos De Leon under the supervision of Dr. Marc Cox, purchased from the
Sigma Rare Chemicals Library (Sigma-Aldrich, St. Louis, MO) and also assayed for
their effects on FKBP52-regulated AR-P723S, AR and GR function. Chem Draw
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software was used to design the structural modifications of the additional chemical
compounds in order to determine the active motifs of the inhibitory molecules.
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Figure 2.1. Representation of the Yeast-Based Compound Library Screen.
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Figure 2.1. Representation of the Yeast-Based Compound Library Screen.
Overnight saturated cultures of the AR-responsive -galactosidase reporter strains
exogenously expressing human FKBP52 and AR-P723S (Tester) or wild type AR alone
(control) were diluted back to an OD600 of 0.08 and incubated at 30.0 C with shaking
until log phase growth was observed (OD600 of approximately 0.1). The cultures were
then aliquoted at 100 l per well followed by the immediate addition (time 0) of library
compounds at 50 M. Hormone was added at 1 hr later followed by the addition of galactosidase substrate at 2 hrs after initial compound addition. Luminescence from the
wells was measured 2 hours post compound addition. This assay was designed to
identify any compound that inhibited FKBP52 regulated receptor activity in the tester
strain, but not inhibit AR function alone in the absence of FKBP52. The AR alone control
strain also controlled for general toxicity. FK506 was used as positive control.
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Mammalian cell lines. Mouse embryonic fibroblast cells isolated from homozygous
52KO embryos (52KO MEF) were previously described [79]. The MDA-kb2 cells,
obtained commercially from the American Type Culture Collection (ATCC), were also
described previously [80, 81]. HeLa, 22Rv1, and VCaP cells were obtained
commercially (ATCC). LNCaP cells were obtained from Dr. Donald Tindall (Mayo Clinic,
Rochester, MN). LAPC4 cells were obtained from Dr. Charles Sawyers and Robert
Reiter. All cells were maintained in the presence of 10% fetal bovine serum and 5%
CO2 at 37°C with the exception of MDA-kb2 cells. MDA-kb2 cells were grown in the
absence of CO2 at 37.0 °C. 52KO MEF and HeLa cells were maintained in MEM-EBSS
medium with 2 mM L-glutamine, LNCaP and 22Rv1 cells were maintained in RPMI1640 medium, MDA-kb2 cells were maintained in L-15 medium, and LAPC4 and VCaP
cells were maintained in DMEM medium. At 24 hrs prior to experiments, cells were
culture in medium lacking phenol red and charcoal-stripped FBS.

LNCaP, LAPC4, and VCaP prostate cancer cells all express endogenous AR and
are sensitive to androgens. LNCaP cells are characterized by the presence of the AR
T877A mutation. Both AR alleles are wild type in LAPC4 cells. VCaP cells are
characterized by endogenous AR gene amplification and, although they can respond to
androgens, are also capable of androgen-independent growth. The 22Rv1 cell line was
derived from a xenograft that was serially propagated in mice after castration-induced
regression and relapse of the parental, androgen-dependent CWR22 xenograft. The AR
mutation occurred during the progression to androgen independence. AR in 22Rv1 is
characterized by an in-frame tandem duplication of exon 3 that encodes the second zinc
30

finger of the AR DNA-binding domain [82, 83]. 22Rv1 cells also express a constitutively
active truncated form of AR lacking the C-terminal hormone binding domain. As a result,
22Rv1 cells can both respond to hormone and display hormone-independent growth.

Toxicity Analysis in Mammalian Cells. Two methods were used to measure cell
viability of HeLa and Mouse Embryonic Fibroblast (MEF-FKBP52KO) cells. The first
one to be used was trypan blue dye exclusion. This method determines cell viability
based on cell membrane integrity. Cells were plated in 6-wells plates at a cell density of
2x106 cells/well. After the cells attached they were treated with different concentrations
of inhibitor for 24hrs. The cells were trypsinized and centrifuged for 5 minutes at 100xg.
The cell pellet was resuspended in 1mL of 1XPBS and 10uL of cell suspension mixed
with 10 uL of 0.4% trypan blue. The mixture was incubated for 3 minutes at room
temperature followed by cell counting in the hemocytometer (viable cells were unstained
unlike nonviable cells). The second method for testing cell viability was the MTT assay
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrzolium bromide) obtained from Invitrogen
(Cat. M-6494) which measures mitochondrial redox potential. Cells were plated in a 96well plate at a density of 5x103 cells/well. After the cells attached they were treated with
different inhibitor concentrations for 24 hours. The media was removed and replaced
with fresh culture media and 10 uL of 12 mM MTT reagent added to each well. The
samples were incubated at 37.0 oC for 4 hours followed by the addition of 100 uL
sodium dodecyl sulfate Hydrochloric acid solution (SDS-HCL). The samples were
incubated again for a period of 4-18 hours and the absorbance read in the
spectrophotometer (570 nm).
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Luciferase reporter assays. Plasmid transfections in 52KO MEFs were performed
using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Cells were plated in 6wells plates at a cell density of 2x106 cells/well (approximately 80% confluence) and
plasmid transfections at a DNA (µg) to lipofectamine ratio of 1:3 in MEM-EBSS lacking
fetal bovine serum for four hours. The plasmids used for these assays were: hormoneresponsive firefly luciferase reporter (400 ng per well), mammalian expression vector
(pCI-neo; Promega, Madison, WI) expressing the androgen receptor (800 ng per well),
pCI-neo alone or expressing FKBP52 (800ng), and a constitutive β-galactosidase
expression plasmid (50ng) as a transfection control. At 24 hrs post transfection the
cells were treated with the indicated inhibitor concentrations for 1 hr followed by
treatment with DHT (concentrations used corresponded to the EC50 for DHT at each
condition) for 16 hrs and 37.0 oC. The cells were then lysed in 150 µl of M-PER
mammalian protein extraction reagent (Thermo Fisher Scientific Inc., Rockford, IL)
supplemented with Complete mini EDTA-free protease inhibitors (Roche, Indianapolis,
IN) per well and incubated at room temperature for 10 min. For luciferase activity, 100
µl of luciferase assay reagent (Promega) was added to 40 µl of cell lysate in an opaque
96-well plate and light emission was measure in the luminescence plate reader
(Luminoskan Ascent, Thermo Labsystems). For β-galactosidase activity, 100 µl of
Tropix Gal-screen reagent (Applied Biosystems, Foster City, CA) was added to 10 µl of
cell lysate in a white 96-well plate and incubated for 2 hrs at room temperature. βgalactosidase activity was measured using a luminescence plate reader. Differences in
transfection efficiency were normalized by dividing RLU (relative light units) by βgalactosidase activity. The MDA-kb2 cells stably express an androgen-responsive firefly
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luciferase reporter construct as previously described [81]. Thus, no plasmid
transfections were necessary in this cell line. MDA-kb2 cells were treated with 0.2 nM
DHT (EC50 for DHT in this cell line) and the indicated concentrations of inhibitors for 20
hrs followed by cell lysis and luminescence measurement using Bright-Glo (Promega)
Luciferase assay reagent according to the manufacturer’s instructions. The assays
shown for all cell lines are representative of at least three independent assays with each
data point measured in triplicate.

Western blot analysis. For the assessment of AR nuclear translocation cells were
grown to 50% confluence, washed in serum-free medium and re-cultured for 48 hours in
fresh medium followed by addition of MJC13 at the concentrations indicated. After an
additional 24 hrs hormone was added (R1881 or fetal bovine serum) and cells cultured
for an additional 2 hrs. Cells were lysed and separated into nuclear and cytosolic
fractions according to previously established methods. Detection of AR in the nucleus
and the cytosol was performed by polyacrylamide gel electrophoresis followed by
Western blotting. For Western blots, cells were lysed 48 hrs after transfection with the
M-PER mammalian protein extraction reagent (Thermo Fisher Scientific Inc.) as
described above. To determine protein concentration the Coomassie Plus protein assay
reagent (Thermo Fisher Scientific Inc.) was used. Typically 20 µg of total cellular protein
was separarted on a 10-20% Criterion gel (Bio-Rad, Hercules, CA) and transferred to a
Polyvinylidene Difluoride membrane. The mouse monoclonal antibody directed against
FKBP52 (HI52D) was used as previously described [84]. The mouse monoclonal
antibody directed against Hsp90 (H90-10) was generously provided by Dr. David Toft
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(Mayo Clinic, Rochester, MN). The polyclonal rabbit antibody directed against AR (N-20;
Santa Cruz Biotechnology, Santa Cruz, CA), the mouse monoclonal antibody directed
against glyceraldehyde phosphate dehydrogenase (6C5; Biodesign International, Saco,
MN), and the alkaline phosphatase-conjugated anti-rabbit and anti-mouse secondary
antibodies (Southern Biotechnology Associates, Birmingham, AL) were all obtained
commercially. The bands were visualized using an Immuno-star substrate (Bio-Rad)
and exposing to x-ray film.

Electrospray Ionization-Mass Spectrometry (ESI-MS) Analysis. Cell samples were
dissolved in methanol containing 0.1% formic acid and injected by infusion (500 nL/min)
or static nanospray (EconoTip, New Objective) into an ElectroSpray Ionisation-Time-ofFlight Mass Spectrometry (ESI-QTOF-MS) analyzer (Qtof-1, Micromass, Waters).
Spectra was collected in the positive-ion mode at 50-2500 mass-to-charge (m/z) range.
The nanospray source was set at 1.0-2.5 kV, cone voltage 35 V, and the source and
desolvation temperatures at 110 and 150oC, respectively.
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III.

Results

Identification of Small Molecule Inhibitors of FKBP52-Enhanced AR Function.
A yeast-based screen of a compound library (Figure 2.1) resulted in the identification of
two candidate inhibitors (H7 and H8) that specifically inhibited FKBP52-enhanced ARP723S function (the P723S mutant was used to increase sensitivity in the assay). H8,
though functional, was disregarded in this study as it was found to be specific for
FKBP52-enhanced AR-P723S, but had no effect on wild type AR (Figure 2.4). In
addition to H7, we assessed 28 additional compounds, designed by Johanny Tonos De
Leon under the supervision of Dr. Marc Cox, that represented slight chemical
modifications of H7 for effects on FKBP52-enhanced wild type AR, AR-P723S, and GR
signaling in the yeast-based reporter assay. The complete set of yeast-based SAR data
is illustrated in both qualitative (Figure 2.3) and quantitaive (Figure 2.4 and Table 2.1)
format. In addition, the results and chemical structures for two of the most promising
compounds, MJC01 and MJC13, and the original hit compound H7 are shown in Figure
2.5. The control strain contained only the receptor in the absence of FKBP52 while all
other strains contained FKBP52 allowing the results to be normalized to show only
FKBP52-specific effects. While H7 produced maximal inhibition at 100 µM (Fig. 2.5A),
MJC01 and MJC13 displayed increased potency with maximal inhibition between 5 and
10 µM (Fig. 2.5B-C). All of the FKBP52-specific compounds identified displayed at least
some general receptor inhibition at high doses. MJC01 generally inhibited AR signaling
in the absence of FKBP52 at the 100 µM dose as evidenced by the upward trend in the
dose response curve at that dose (Fig. 2.5B). In contrast, MJC13 was FKBP52-specific
at concentrations as high as 100 µM (Fig. 2.5C), although it did produce some general
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receptor inhibition at significantly higher doses. To further control for specificity we
assessed these compounds for their effect on the expression of a galactose-inducible βgalactosidase reporter (Figure 2.6). Neither MJC13 nor MJC01 affected inducible
reporter expression indicating that the inhibition observed is not due to general effects
on transcription, translation, or protein stability. Some of the compounds tested,
including MJC01 (Figure 2.5B), also differentially affected wild type AR and AR-P723S
reporter activity. In addition to the fact that the compounds can affect receptor function
alone in the absence of FKBP52 at high doses suggests that the compounds bind the
AR hormone binding domain and possibly specifically at the BF3 surface. This
hypothesis is also supported by the fact that FKBP52-specific inhibitors are structurally
similar to the fenamic acids, which were previously shown to bind the BF3 surface. For
comparison, we also assessed the potential FKBP52-specific effects of various fenamic
acid derivatives. Figure 2.5D revealed that the prototypical BF3-binding AR inhibitor
flufenamic acid displayed no FKBP52-specific effects. Thus, although structurally similar
they are functionally distinct. Many of the compounds tested also differentially affected
AR and GR signaling. MJC13 was slightly more specific for FKBP52-enhanced AR
signaling as compared to GR (Figure 2.5C). It is important to point out that all of the
fenamic acids tested, with the exception of mefenamic acid, were not specific for
FKBP52 but generally inhibited AR and GR signaling to varying degrees. Mefenamic
acid had no effect on receptor function in the presence or absence of FKBP52. MJC13
displayed higher potency and better selectivity for AR than any other compound tested.
Although MJC01 has a higher potency than H7 it is less selective for FKBP52 as
evidenced by the reduction in FKBP52-specific inhibition at the 100 μM dose. Thus, at
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the current time, MJC13 is the most promising lead compound that displays little effect
on AR in the absence of FKBP52 and may selectively target AR better than any other
compound tested.
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Figure 2.2. Structure of FKBP52-Specific Inhibitors.
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Figure 2.2. Structure of FKBP52-Specific Inhibitors.
FKBP52 inhibitory molecules are structurally similar to fenamic acids [85, 86] and some
small molecules known to bind the androgen receptor BF3 surface [87]. However, unlike
the known BF3 binding molecules which generally inhibit AR function in the 100 uM
range, our compounds specifically inhibit FKBP52-enhanced AR function at 100 fold
lower concentration and, thus, are effective at concentrations that are below those
required for AR function in the absence of FKBP52. The result of the initial highthroughput screen was the identification of one compound (H7) that inhibits FKBP52enhanced AR function, but not AR function alone in yeast (figure 2.5). However, the
compound showed weak inhibitory activity in our assay. In order to find compounds with
higher activity and better AR selectivity, we analyzed this hit and identified 28 additional
compounds that represent slight structural modifications to H7. Note that compounds
MJC19 through MJC25 are small molecules that have been previously described to bind
to the BF3 surface. H7 derivatives include modification of the phenyl moiety by
introducing various substituents including nitro, hydroxyl, alkoxy, aryl and alkyl groups
or aromatic heterocycles and modification of the spacer between the cyclohexyl and
phenyl moieties.

39

Figure 2.3. Qualitative Analysis of SAR Data.
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Figure 2.3. Qualitative Analysis of SAR Data. All H7 derivatives tested were assigned
an MJC number and placed on qualitative tables. The degree of inhibition is denoted but
positive signs with +++ equally maximal inhibition. The specificity of inhibition towards
FKBP52-enhanced receptor function is denoted by a black box and general inhibition of
the receptor in the absence of FKBP52 is denoted by a gray box. When a compound
has both, black and grey boxes, the molecule shows specific inhibition at low doses and
a general inhibitory effect at higher doses.
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Figure 2.4. Normalized SAR Data.
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Figure 2.4. Normalized SAR Data. Yeast reporter strains expressing wild type AR in
the absence (control, black closed circles) or presence (AR, red closed squares) of
FKBP52, and the AR-P723S point mutant in the absence (control, black closed circles)
or presence of FKBP52 (AR-P723S, blue upright triangles), and GR in the absence
(control, black closed circles) or presence of FKBP52 (GR, green down-facing triangles)
were treated with a range of concentrations of the indicated compounds in the presence
of DHT. The data were normalized to show only effects on FKBP52-enhanced receptor
function by calculating the percent reduction in the control strain for each data point and
adding that back to each data point for both the control and FKBP52 tester strains.
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Table 2.1 IC50 Values Determined in SAR Assays
Inhibitor

IC50 WT AR (µM)

IC50 P723S (µM)

IC50 GR (µM)

H7

48.37

63.10

3062

H8

-

0.305

324.3

255

194.4

56.31

-

256

-

-

-

MJC01

7.334

255.1

12.79

MJC02

62397

-

329.08

MJC03

176.1

6.249

-

MJC04

-

125.7

-

MJC05

-

6.461

-

MJC06

169259

51.23

54.85

MJC07

9.067

14.26

39.16

MJC08

168.5

408.5

1525

MJC09

105.7

41.40

786.9

MJC10

64.95

165.5

126.9

MJC11

-

-

-

MJC12

-

-

-

MJC13

4.31

9.41

502.8

MJC14

863.4

10174

-

MJC15

-

-

369.9

MJC16

-

-

-

MJC17

-

166.5

3626

MJC18

97.03

137.6

458.7

MJC19

-

-

9154

MJC20

9.29

-

0.256

MJC21

-

-

-

MJC22

-

-

-

MJC23

-

8421

-

MJC24

-

-

733.60

MJC25

-

647.20

-

MJC26

-

11634

-

MJC27

109.8

0.553

15.79
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Figure 2.5. Analysis of Inhibitors Specific for FKBP52-Regulated Receptor
Function in Yeast.
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Figure 2.5. Analysis of Inhibitors Specific for FKBP52-Regulated Receptor
Function in Yeast. Yeast reporter strains expressing wild type AR in the absence
(control, closed circles) or presence (AR, closed squares) of FKBP52, and the ARP723S point mutant in the absence (control, closed circles) or presence of FKBP52
(AR-P723S, closed triangles) were treated with a range of concentrations of the
indicated compounds in the presence of DHT. H7 (A) is the original hit identified from
the library screens, MJC01 (B) and MJC013 (C) are the current lead compounds, and
flufenamic acid (D) is a known AR inhibitor that associates with the BF3 surface. The
structures of the molecules are illustrated above each respective graph. The data were
normalized to show only effects on FKBP52-enhanced AR function by calculating the
percent reduction in the control strain for each data point and adding that back to each
data point for both the control and FKBP52 tester strains. Thus, a hormesis-like effect
as seen for MJC01 at 100 µM (B) indicates that the receptor in the absence of FKBP52
was generally inhibited at that dose (FKBP52 independent effects).
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Figure 2.6. The FKBP52 Inhibitors do not Affect General Transcription,
Translation, or Protein Stability.
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Figure 2.6. The FKBP52 Inhibitors do not Affect General Transcription,
Translation, or Protein Stability. Galactose-inducible -galactosidase reporter
expression in yeast (gray bars) and constitutive renilla luciferase reporter expression in
FKBP52-deficient mouse embryonic fibroblasts (black bars) was assessed in the
presence or absence of the indicated inhibitors at 100 M.
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The AR BF3 Surface is a Putative FKBP52 Interaction/Regulatory Surface
The stoichiometry and identity of proteins forming cytoplasmic chaperone
complexes with androgen receptor are not known in detail. FKBP52, a cochaperone,
associates with steroid hormone receptor-chaperone complexes and is a specific
positive regulator of AR, PR and GR function [25, 33, 88]. Although FKBP52 functionally
associates with three steroid hormone receptors indirectly through Hsp90 binding
several lines of evidence suggest that FKBP52, in particular the FKBP52 FK1 domain,
directly binds to the receptor hormone binding domain within the context of the Hsp90
chaperone complex [89]. To identify this potential FKBP52 interaction surface on AR we
aligned receptor amino acid sequences and identified seven amino acid residues (L805,
C806, K845, R846, R840, F673, and P723) within the AR hormone binding domain that
are conserved in the FKBP52-regulated receptors, PR and GR, but differ in
mineralocorticoid receptor (MR). Interestingly, all seven have been found mutated in
prostate cancer and/or androgen insensitivity syndrome (AIS) patients (McGill Androgen
Receptor Gene Mutations Database, http://androgendb.mcgill.ca/). An analysis of the
AR hormone binding domain crystal structure revealed that these residues delineate a
surface region that overlaps with the recently described AR BF3 surface [90] (Figure
2.7B-C). In addition, mutation of P723, within the BF3 surface, results in a receptor that
is hypersensitive to FKBP52 potentiation [33]. To assess the effects of the additional
residues on FKBP52 regulation of AR function we systematically mutated each of the
residues and assessed the mutant receptors for their ability to respond to FKBP52
potentiation in yeast-based AR-mediated reporter assays. In all cases the specific
mutations made were based on mutations that have been identified in prostate cancer
49

and/or AIS patients. Many of these mutant receptors lost activity and did not respond to
FKBP52. However, we identified two additional mutations, F673P and C806Y, which
resulted in AR hypersensitivity to FKBP52 potentiation (Figure 2.6A), although not to the
same degree as P723S. As highlighted in Figure 2.7A F673 contacts P723 within the
BF3 surface and C806, although not a surface residue, is buried directly below p723
and F673. Thus, the BF3 surface, particularly the region containing F673 and P723, is a
putative FKBP52 interaction and/or regulatory surface.
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Figure 2.7. Mutations in the AR BF3 Surface Result in Increased Dependence on
FKBP52 for Function.
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Figure 2.7. Mutations in the AR BF3 Surface Result in Increased Dependence on
FKBP52 for Function. A. Yeast reporter strains for wild type AR or the indicated AR
point mutants were transformed with an empty plasmid vector or plasmid expressing
human FKBP52. The yeast were induced with DHT and assessed for β-galactosidase
expression. The data are plotted as fold change of the activity measured in the
presence of FKBP52 over the activity in the absence of FKBP52 and are representative
of at least five independent experiments. B-C. The AR hormone binding domain crystal
structure showing the location of the mutated residues in relation to the BF3 surface is
shown. The BF3 surface is highlighted in green, bound DHT is highlighted in blue, and
the F673, P723, and C806 residues are highlighted in purple, orange and yellow
respectively.
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Compounds Effectively Target FKBP52-Enhanced AR Signaling in Mammalian
Cells
The compound library screen and subsequent structure activity relationship
(SAR) analysis were all performed in yeast-based assays. To assess the effects of the
compounds in higher vertebrate model systems we first tested the compounds for the
ability to inhibit AR signaling in MDA-kb2 cells (Figure 2.8A-B). This cell line contains a
stable androgen-responsive luciferase reporter construct and serves as a rapid
mammalian assay for assessing AR inhibition [81]. This cell line expresses endogenous
FKBP52 and can’t be used to distinguish FKBP52-specific effects. MDA-kb2 cells were
treated with a range of concentrations of the indicated compounds for 20 hrs and
assessed for both cell viability and AR-dependent expression of the luciferase reporter
gene. The compounds displayed no cellular toxicity in MDA-kb2 cells as assessed by
ATP quantification (Figure 2.8A). H7, MJC01, and MJC13 all inhibited AR-mediated
expression of the luciferase reporter with half maximal inhibitory concentrations (IC 50) of
24.56, 3.60, and 1.79 µM respectively (Figure 2.8B). These data correlate well with
those observed in the yeast-based assays.
Mouse embryonic fibroblasts (MEFs) derived from FKBP52-deficient mice
(52KO) [88] is the only higher vertebrate model system that contains a true FKBP52negative background in which to test the compounds for FKBP52-specific effects. Thus,
we setup AR-mediated luciferase reporter assays in 52KO MEF cells in the presence or
absence of an FKBP52 expression vector and assessed the compounds for cellular
toxicity and FKBP52-specific inhibition of androgen-dependent luciferase expression.
None of the compounds produced cellular toxicity up to the maximum soluble
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concentration of 250 µM as assessed by trypan blue dye exclusion & MTT assays
(Figure 2.8C). MJC01 and MJC13 specifically inhibited FKBP52-enhanced AR-mediated
expression of the luciferase reporter gene with IC50 values of 0.62 and 0.45 µM
respectively (Figure 2.8D and E). Consistent with the data obtained in the yeast-based
assays MJC01 displayed significantly higher FKBP52-independent inhibition of AR
function (Figure 2.8D) as compared to MJC13. MJC13 also produced general AR
inhibition in this system at concentrations above 50 µM (data not shown). To further
evaluate compound specificity, the compounds were assessed for effects on
constitutive renilla luciferase expression in the 52KO MEF cells (Figure 2.6). Neither
MJC13 nor MJC01 affected the constitutive expression of renilla luciferase.
Western blots using lysates prepared from the cells tested as described in Figure
5E showed increasing levels of AR and FKBP52 protein that directly correlated with
increasing concentrations of MJC13 (Figure 2.8F). Repeated experiments revealed that
the degree of stabilization varied between experiments and one of the more dramatic
examples is shown in Figure 2.8F. Variable stabilization of Hsp90 and p23 protein levels
was also observed, but to a lesser degree than that seen for FKBP52 and AR.
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Figure 2.8. Effects of the Inhibitors on FKBP52-Regulated AR Function in
Mammalian Cells.
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Figure 2.8. Effects of the Inhibitors on FKBP52-Regulated AR Function in
Mammalian Cells. A-B. MDA-kb2 cells carrying a stably transfected AR-responsive
luciferase reporter were treated with 0.2 nM DHT and a range of concentrations
assessed for cell viability (A) and AR-dependent expression of the luciferase reporter
(B). The IC50 values for the compounds are shown in the legend. C-E. Luciferase
reporter assays in 52KO mouse embryonic fibroblast cells in the presence or absence
of FKBP52 were performed. Transfected cells were treated with DHT and a range of
concentrations of the indicated compounds and assessed for cell viability (C) and ARdependent expression of the luciferase reporter (D-E). The IC50 values for MJC01 (D)
and MJC13 (E) are shown in the legends. F. Lysates were prepared from 52KO MEF
cells transfected with AR and FKBP52 expression vectors that were treated with DHT
and a range of MJC13 concentrations (0, 0.05, 0.1, 0.5, 1, 5, 10, 50, and 100 µM) for 24
hours. Lysates were immunoblotted for AR, FKBP52, and GAPDH as a loading control.
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Purity of MJC Molecules. One concern that often arises when working with small
molecule inhibitors is the fact that the inhibitory activity observed could be due to
impurities within the sample. Thus, mass spectrometry was performed with the lead
compounds to assess purity. The compounds tested showed approximately 95% purity
(Figure 2.9).
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Figure 2.9. Purity of MJC Molecules.
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Figure 2.9. Purity of MJC Molecules. Electrospray ionization-mass spectrometry (ESIMS) analysis was used to assess compound purity. The compounds tested showed
approximately 95% purity. A. MJC13 and B. H7.
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CHAPTER 3
CHARACTERIZATION OF ANDROGEN RECEPTOR-FKBP52 INTERACTIONS IN
THE PRESCENCE OF THE INHIBITORS AND THE EFFECTS ON RECEPTOR
LOCALIZATION

I.

Rationale
We have identified a series of small molecules that specifically inhibit FKBP52-

enhanced receptor function. Given that a functional screen was used for candidate
inhibitor identification, the target site(s) are unknown. Whether MJC13 and active
derivatives bind directly to FKBP52 and disrupt FKBP52 interaction with the receptorHsp90 complex remains to be determinate. The fact that the MJC molecules are
structurally similar to fenamic acid molecules previously shown to bind the BF3 surface
and the findings that they can differentially affect wild type AR and AR-P723S function
suggest that the molecules may target the AR BF3 surface. This notion is further
supported by the fact that the AR BF3 surface is hypothesized to be an FKBP52
interaction/regulatory surface. The studies detailed in this chapter sought to
characterize the inhibitor target site and to use that information to identify the
mechanism of inhibition.
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II.

Materials and Methods

Co-Immunoprecipitation. Cells were plated in 10 cm dishes at 10 % confluency in
RPMI 1640 medium containing 10% charcoal-stripped fetal bovine. After 24 hours,
MJC13 or vehicle was added to a final concentration of 30 M. After an additional 24
hours, R1881 was added to a final concentration of 300 pM and the cells were lysed two
hours later in TMNSV buffer [50 mM Tris·HCl (pH 7.4), 0.1% Nonidet P-40, 20 mM
Na2MoO4, 150 mM NaCl, 2 mM Na3VO4] supplemented with a Complete™ protease
inhibitor tablet (Roche). Protein concentrations were measured with a BCA™ assay kit
(Thermo Scientific) and 1 ml of 1 mg/ml cell lysates prepared. Thirty microliters of
recombinant Protein G agarose beads were added to each sample and rotated for one
hour at 4 oC; 10 g of immunoprecipitating antibody was then added to each sample
and rotated for an additional two hours at 4 oC. Beads were washed four times with
TMNSV buffer and boiled in SDS sample buffer for five minutes. Eluted proteins were
subjected to SDS-PAGE, transferred to nitrocellulose membrane, and blotted with
specific antibody for the protein of interest. Anti-AR (N-20, Santa Cruz), anti-Hsp90
(SPA-835,Stressgen), and anti-FKBP59 (SRA-1400, Stressgen) were used for both
immunoprecipitation and immunoblotting.

Androgen Receptor . Early stage Prostate Cancer cells (LNCaP cells) were
maintained in RPMI media supplemented with 10% fetal bovine serum and 0.1% Lglutamine (GIBCO). At 50% confluence, cells were washed several times in serum-free
RPMI-1640 medium and re-cultured for 48 hours in RPMI-1640 medium containing 10%
charcoal-stripped fetal bovine serum. At that time, MJC13 was added to a final
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concentration of 30 μM. After an additional 24 hours, hormone was added (0.1 nM) and
cells cultured for an additional 2 hours. Cells were lysed and separated into nuclear
and cytosolic fractions according to previously established methods [91]. Quantification
of AR in the nucleus and the cytosol was performed by Western blotting with an ARspecific antibody (N-20 from Santa Cruz) followed by SDS polyacrylamide gel
electrophoresis.

Biacore/Binding Affinity of MJC13 to the AR-HBD. These experiments were
performed by Dr. Robert Fletterick’s laboratory at the Univiersity of California at San
Francisco. There are only a few laboratories in the world that can perform Biacore
studies with the AR hormone binding domain (AR-HBD) since this structure is very
unstable. Dr. Fletterick kindly offered to perform this experiment for us; therefore there
is no detailed protocol for this methodology.

Scintillation Proximity Binding Assays. The basic protocol for the scintillation
proximity binding assay with AR LBD was performed as previously described [92].
Liquid handling was carried out using an automated liquid handling system (Biomek
FX). To a 384-well Ni-chelate coated Flashplate® (PerkinElmer) 50 µl of 5 µM
recombinant AR LBD was added in assay buffer (50 mM HEPES, 150 mM Li 2SO4, 0.2
mM TCEP, 10% glycerol, 0.01% Triton X-100, pH 7.2). After 60 min incubation the
protein solution was discarded, followed by washes with assay buffer. Next, 25 µl of the
serially diluted inhibitors in assay buffer containing 10% DMSO were added to each well
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followed by an additional 25 µl of a 3H DHT radioligand solution in assay buffer with a
final assay solution of 5% DMSO. The plates were sealed and allowed to equilibrate for
5 hrs at 4°C. [3H]-DHT was used at a final concentration of 20 nM. Radiocounts were
measured using a TopCount Microplate Scintillation and Luminescence Counter
(Packard Instrument Company). All samples were tested in triplicates.

Fluorescence Polarization Assay. The fluorescence polarization assay was previously
described [93]. In short, 20 μl of protein mixture (6.25 μM recombinant AR LBD plus
DHT and 0.0125 μM SRC2-3 peptide in dilution buffer; final concentration 50 μM
compound, 4% DMSO) was added to 1.2 μl of respective compound solubilized in
DMSO in a 384-well plate (Costar 3710). The plated conditions were equilibrated for 5
hrs before total fluorescence and fluorescence polarization measurements (excitation
485 nm, emission 530 nm) on an Envision (Perkin Elmer).

AR BF3 Docking Simulations. MJC01 and MJC13 were docked into the BF3 pocket of
androgen receptor using DOCK 3.5.54 [94, 95]. Seven AR complex structures (pdb
IDs, 2PIT, 2PIU, 2PIV, 2PIW, 2PIX, 2PKL and 2QPY) were docked individually to
capture some receptor conformational flexibility. The protein in the complex structure
was used as rigid receptor, without water molcules. The original crystal ligand was
used to generate matching spheres to place the new compound. Multiple
conformations of the compound were pre-generated and placed in the binding pocket
guided by the matching spheres. Ligand poses were scored by their interactions with
the protein, through a grid-based method calculating van der Waals, electrostatic
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interactions and ligand desolvation energy. The top scoring poses against different
receptor conformations were visually examined. The pose selected for each ligand was
the one with the best docking scores and also the best complementary shape with the
protein binding pocket (pdb ID, 2PIX).
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III.

Results

Defining the Binding Locus for MJC13
AR likely adopts an altered conformation when it forms complexes with FKBP52 and
HSP90. MJC13 may bind to these proteins directly or indirectly via protein complexes.
In collaboration with Robert Fletterick’s laboratory (University of California San
Francisco) we first assessed the case for direct association of FKBP52 to DHT bound
and apo AR using surface plasmon resonance (SPR) studies. We could not identify any
interactions between the two proteins. Thus, we next tested binding interaction between
FKBP52 and compound H7 or MJC13 and as well found no interaction (data not
shown).
To rule out interaction of these compounds with the hormone binding pocket the
compounds were assessed for their ability to compete with DHT binding in scintillation
proximity binding assays with the recombinant AR hormone binding domain (Fig. 3.1A) .
This work was performed in collaboration with Kip Guy’s laboratory (St. Jude Children’s
Research Hospital). Data from this work revealed that unlabelled DHT was able to
effectively compete for tritiated DHT. However H7, MJC01, and MJC13 did not compete
with DHT for binding within the AR hormone binding domain at relevant concentrations.
Interestingly a slight inhibitory effect was observed in the presence of 100 µM MJC01,
which may explain the general inhibition of receptor function at high doses.
Fluorescence polarization assays of fluorescently labeled peptides from coactivators
with the recombinant AR hormone binding domain were also performed to rule out
interaction at the AF2 site (Fig. 3.1B-C). Fluorescence polarization is shown in Figure
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3.1B and total fluorescence in Figure 3.1C. None of the compounds tested were able to
compete with the SRC2-3 peptide for binding the AF2 site.
In the absence of data directly demonstrating interaction with the AR hormone
binding domain we performed in silico docking simulations to predict the possible
orientation of the molecules on the BF3 surface in collaboration with Yu Chen’s
laboratory (University of South Florida). The poses chosen for illustration in Figure 3.2
had some of the best docking scores (including electrostatic, van der Waals interactions
and ligand desolvation energy) and the best shape complementarity with the binding
pocket. Both ligands make extensive non-polar contacts with residues P723, F673,
L830 and Y834 on the BF3 surface (Fig 3.2A-B). The amide group of the ligand
appears to have favorable electrostatic interactions with the backbone oxygen atom of
P723, although the N-O distance is too far for a hydrogen bond in the current binding
poses (3.7 and 4.5 Angstrom for MJC01 and MJC13, respectively). The poses
resemble that of flufenamic acid in its AR complex structure (pdb ID 2PIX) (Fig. 3.2C).
Like flufenamic acid, the carboxylate group of MJC01 does not form any hydrogen bond
with the protein in the selected pose. It is clear that the poses shown are one of many
that are possible and should be viewed with caution. However, it is interesting that the
poses with the highest docking scores all contained contacts with and/or around the
P723 and F673 residues.
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Figure 3.1. FKBP52 Inhibitors Do Not Bind the AR Hormone Binding Pocket or
AF2.
67

Figure 3.1. FKBP52 Inhibitors Do Not Bind the AR Hormone Binding Pocket or
AF2. A. A scintillation proximity binding assay using purified AR LBD is shown. Nickelcoated wells preincubated with 6xhistidine-tagged AR LBD were treated for 5 hours with
a range of concentrations of the indicated compounds or cold DHT in the presence of
20 nM tritiated DHT and assessed for bound radioactivity. B. A fluorescence polarization
assay using purified AR LBD is shown. Purified AR LBD preincubated with the
fluorescently labeled SRC2-3 peptide was treated for 5 hours with a range of
concentrations of the indicated compounds or non-labeled SRC2-3 peptide and
assessed for fluorescence polarization and total fluorescence.
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Figure 3.2. AR-Inhibitor Docking Simulations.
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Figure 3.2. AR-Inhibitor Docking Simulations. The docking pose of the lead
compounds MJC01 (A), MJC13 (B) and the crystal pose of flufenamic acid (C) on the
BF3 surface of androgen receptor (protein databank number 2PIX). The poses shown
were chosen based on the best docking score (including electrostatic, van der Waals
interactions and ligand desolvation energy) and the best shape complementarity with
the binding pocket. The carbon atoms of the protein and ligand are shown in cyan and
yellow (MJC01)/green (MJC13)/light green (flufenamic acid) respectively. Nitrogen,
oxygen, hydrogen and fluorine atoms are shown in blue, red, white and light blue,
respectively.
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MJC13 Prevents Receptor-Hsp90 Complex Dissociation and Nuclear
Translocation in Cellular Models of Prostate Cancer
The effects of MJC13 on the stability of AR and associated chaperones is similar
to that observed in the presence of non-hydrolyzable ATP analogues or sodium
molybdate, which prevent hormone-dependent receptor-Hsp90 complex dissociation.
To test the effects of MJC13 on complex formation and/or hormone-dependent complex
dissociation we performed co-immunoprecipitations of FKBP52, AR and Hsp90 in
lysates from cellular models of androgen-responsive (LNCaP and LAPC4) and
hormone-refractory (22Rv1) prostate cancer cells grown in the presence or absence of
hormone and MJC13 (Fig. 3.3). The ability of FKBP52 to bind the AR-Hsp90 complex in
co-immunoprecipitations from prostate cancer cell lysates was unaffected while the
addition of hormone resulted in complex dissociation as determined by a loss in the
ability of FKBP52, AR, and Hsp90 co-precipitating. However, complex dissociation in
the presence of hormone was abrogated by the addition of MJC13 in LNCaP, LAPC4,
and 22Rv1 cells (Fig. 3.3A, C, and D respectively). In addition, Western immunoblots of
fractionated lysates prepared from LNCaP, LAPC4, and 22Rv1 cells grown in the
presence or absence of hormone and MJC13 revealed that hormone-induced AR
translocation to the nucleus was blocked by the drug (Fig. 3.3B, D, and F respectively).
MJC13 inhibition of AR nuclear translocation could be overcome by high hormone
concentrations in LNCaP cells (Fig. 3.3B), which may reflect the lack of receptor
dependence on FKBP52 for function at higher hormone concentrations [25].

71

Figure 3.3. Effects of MJC13 on Receptor-Hsp90 Complex Dissociation and
Nuclear Translocation in Early and Late Stage Prostate Cancer Cells.
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Figure 3.3. Effects of MJC13 on Receptor-Hsp90 Complex Dissociation and
Nuclear Translocation in Early and Late Stage Prostate Cancer Cells. The effects
of MJC13 on hormone-dependent AR-Hsp90 complex dissociation and AR nuclear
translocation were assessed in LNCaP (A-B), LAPC4 (C-D), and 22Rv1 (E-F) cells by
co-immunoprecipitation and Western blot respectively. Lysates from cells grown in the
presence or absence of the indicated concentrations of hormone and MJC13 for 24
hours were subjected to immunoprecipitation with either an antibody directed against
FKBP52 (A) or AR (C and E) and immunoblotted for the indicated proteins. Fetal bovine
serum served as the source of hormone in A. Lysates prepared from cells treated with
the indicated concentrations of ligand and MJC13 for 24 hours were also fractionated
and immunoblotted for AR in both the cytosol and nucleus (B, D, and F). These
experiments were performed in triplicates.
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CHAPTER 4
CHARACTERIZATION OF THE EFFECTS INHIBITORS HAVE ON HORMONEDEPENDENT GENE EXPRESSION AND CELL PROLIFERETION IN PROSTATE
CANCER CELLS

I.

Rationale

Prostate cancer progression mostly depends on the availability of viable androgen
receptor. The inhibitory molecules described herein not only impaired FKBP52dependent AR function and signal transduction but also prevented the receptor from
translocating into the nucleus and promoting gene expression. FKBP52 inhibitors
identified were characterized and assessed for their ability to inhibit androgendependent prostate specific antigen secretion (PSA), in addition to measuring the effect
each compound has on human prostate cancer cell proliferation (early and late stage).
PSA is a serine protease that is secreted in small amounts by healthy prostate cells and
is a major component of the seminal fluid; therefore it is used as a biomarker for PCa
development [41]. PSA in serum is also used to monitor the success of therapies
currently used for the treatment of PCa such as radiation, androgen ablation or
prostatectomy and for monitoring the recurrence in PCa therapy. PSA has been
detected in serum since 1990 for screening of PCa because it is an AR-regulated gene
[42]. In addition to PSA, we also chose to assess the androgen-dependent expression
of FKBP51, which is related to FKBP52, but does not regulate receptor function in
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cellular assays. FKBP51 has recently emerged as a potential prostate cancer biomarker
due to its hormone-dependent expression.
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II.

Materials and Methods

Prostate Cancer Cell Lines. 22Rv1 and VCaP cells were obtained commercially
(ATCC). LNCaP cells were obtained from Dr. Donald Tindall (Mayo Clinic, Rochester,
MN). LAPC4 cells were obtained from Dr. Charles Sawyers and Robert Reiter. All cells
were maintained in the presence of 15% fetal bovine serum and 5% CO2 at 37 °C.
LNCaP and 22Rv1 cells were maintained in RPMI-1640 medium and LAPC4 and VCaP
cells were maintained in DMEM medium. At 24 hrs prior to experiments, cells were
switched to medium lacking phenol red and containing charcoal-stripped FBS. LNCaP,
LAPC4, and VCaP prostate cancer cells all express endogenous AR and are sensitive
to androgens. LNCaP cells are characterized by the presence of the AR T877A
mutation. Both AR alleles are wild type in LAPC4 cells. VCaP cells are characterized by
endogenous AR gene amplification and, although they can respond to androgens, are
also capable of androgen-independent growth. The 22Rv1 cell line was derived from a
xenograft that was serially propagated in mice after castration-induced regression and
relapse of the parental, androgen-dependent CWR22 xenograft. The AR mutation
occurred during the progression to androgen independence. AR in 22Rv1 is
characterized by an in-frame tandem duplication of exon 3 that encodes the second zinc
finger of the AR DNA-binding domain. See Table 3.1 for details on the AR mutations
found in the cell lines.
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Table 4.1. Prostate cancer cell lines used.

Cell line

AR
mutation

p53
mutation

TP53
mutation

22Rv1

H874Y

Q331R

-

CWR22-R1
cell line

LAPC4

WT

A175H,
P72R,
R175H

G11827C

Unique

LNCaP

T877A

-

WT

Unique

Identity

References
[82, 83]

[82, 83]

[82, 83]

[82, 83]
VCaP

WT

A248W

-
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Unique

Enzyme-Linked Immunoadsorbant Assays (ELISA) for PSA
The indicated cells were plated at a density of 2x106 cells/well and treated with a range
of inhibitor concentrations 24 hrs after plating, followed by treatment with 500 pM DHT
for LNCaP cells. VCaP cells were not treated with DHT. Media was collected from each
well daily and stored at -20oC until all the treatments were completed. ELISA plates
(Alpha Diagnostic International) previously treated for the detection of human PSA by
the manufacturer were used. A 25 µl of sample or standard was added to each well with
100 µl of AB-enzyme conjugate and incubated for 30 min at room temperature. The
wells were washed with 300 µl of wash buffer followed by the addition of 100 uL TMB
substrate per well and an incubation period of 15 min at room temperature. The
reaction was stopped by adding 50 µl of stop solution to all wells and the absorbance
measured at 450 nm using the Versa Max microplate spectrophotometer.

Cell Proliferation Assays. Cells were plated in a U-shaped 96-well plate at a density of
3x103 cells/well. After the cells attached they were treated with inhibitor for 1 hour
followed by the addition of 500 pM DHT. The wells were treated with 20 uL of tritiated
thymidine (Isotype - [3H] from Perkin Elmer) for 18 hours. Cells were lysed using a Cell
Harvester (Micro96 Harvester from Skatron Instruments) and lysates were transferred to
a filter paper (FilterMAT Cat # 11731 from Skatron Instruments) and incubated for 1
hour at room temperature. Samples were diluted in 3 ml of scintillation fluid (Scinti
SAFE Econo F (LSC Cocktail) SX-22-5 from Fisher) and subjected to scintillation
counting. All experimental measurements were performed in triplicate.
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Quantitative Real-Time PCR. RNA was isolated using the RNeasy RNA Isolation kit
according to manufacturer's instructions (Qiagen). For reverse transcription, 200 ng of
total RNA was used in a reaction mixture containing 1X TaqMan RT buffer (Applied
Biosystems) and Multiscribe Reverse Trasnscriptase. Reverse transcription was
performed for 10 min at 25 °C, 30 minutes at 48 °C and 5 minutes at 95 °C using the
PE9700 thermal cycler (Applied Biosystems). Real-time PCR primers were designed
using Primer Express software (Applied Biosystems). The number of PCR cycles
needed to reach the fluorescence threshold value is the cycle threshold (Ct). Ct values
for the control (18S rRNA) and PSA gene were determined and relative RNA levels
were calculated by the comparative Ct method as described by the manufacturer.
Experiments were performed in duplicate; data are shown as PSA expression relative to
18S rRNA.
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III.

Results

MJC13 Effectively Blocks AR-Dependent Gene Expression and Proliferation in
Prostate Cancer Cells
The effects of MJC13 on endogenous AR-dependent gene expression were
assessed by analysis of prostate specific antigen (PSA) expression in LNCaP and
VCaP cells. We also assessed the impact of MJC13 on expression of the 51 kDa FK506
binding protein (FKBP51) in these cell lines. FKBP51 has emerged as a potential
hormone-dependent cancer biomarker [96, 97] due to its hormone-inducible expression
(Figure 4.1). However, unlike PSA, FKBP51 is a component of steroid hormone
receptor-chaperone complexes [84, 98, 99] and has recently been shown to promote
AR function in LNCaP cells in a similar manner as FKBP52 [100]. Thus, inhibition of
FKBP51 expression by MJC13 may have therapeutic implications. ELISA analysis of
PSA secretion from LNCaP cells (Figure 4.2A) and VCaP cells (Figure 4.2B)
demonstrated that MJC13 effectively inhibits PSA secretion from both cell lines.
Inhibition of hormone-stimulated PSA secretion from LNCaP cells was more potent as
compared to hormone-independent secretion from VCaP cells. However, in the
presence of hormone MJC13 inhibited PSA secretion from VCaP cells to a similar
degree as in LNCaP. The effects of MJC13 on endogenous levels of PSA and FKBP51
in LNCaP and VCaP cells were assessed by Western immunoblot and densitometry
(Figure 4.2C and D). Representative blots for FKBP51, PSA, and the loading control
GAPDH are shown (Figure 4.2C and D; upper panels). The normalized and averaged
densitometry data from three independent experiments demonstrate that MJC13
reduced endogenous FKBP51 and PSA expression in a dose-dependent manner
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(Figure 4.2C and D; lower panels). To further characterize the effect of MJC13 on AR
transcriptional activity in LNCaP cells, we assessed both endogenous PSA gene
expression and expression of the AR-responsive gene TMPRSS2 by quantitative real
time PCR (Q-PCR). MJC13 effectively abrogated constitutive expression of both ARdriven genes (Figure 4.2E, left panel). In contrast, in 22Rv1 cells, MJC13 was only able
to block androgen-induced (but not constitutive) PSA expression (Figure 4.2E, right
panel). These data are consistent with the fact that 22Rv1 cells express both full length
AR and a constitutively active, truncated AR lacking the LBD (and so predicted to be
insensitive to androgen, FKBP52, and MJC13).
Finally, the effect of these compounds on androgen-dependent prostate cancer cell
proliferation was assessed by tritium incorporation in LNCaP, LAPC4, and 22Rv1 cells
(Figure 4.3). MJC01 and MJC13 both inhibited androgen-dependent cell proliferation at
concentrations consistent with those observed to be effective in reporter assays. MJC01
was less effective at inhibiting androgen-dependent LNCaP cell proliferation compared
to MJC13 (Figure 4.3A). However, the effects of MJC01 and MJC13 in LAPC4 and
22Rv1 cells were similar. For comparison, the effect of a known AR antagonist,
bicalutamide, which interacts with the hormone binding pocket, was assessed. Both
MJC01 and MJC13 were more potent than bicalutamide in these assays.
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Figure 4.1. FKBP51 Expression is Androgen-Dependent.
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Figure 4.1. FKBP51 Expression is Androgen-Dependent. Western blot in LNCAP
cells treated with the indicated range of DHT concentrations demonstrates that FKBP51
expression is increase in a dose-dependent manner after 16 hours of treatment with
DHT.
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Figure 4.2. Effects of MJC13 on AR-Dependent Gene Expression in Early and Late
Stage Prostate Cancer Cells.
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Figure 4.2. Effects of MJC13 on AR-dependent Gene Expression in Early and Late
Stage Prostate Cancer Cells. A-B. ELISA assays to measure PSA secretion were
performed in LNCaP (A) and VCaP (B) cells. Cells were treated with the indicated
MJC13 concentrations in the presence (A) or absence (B) of DHT for 24 hrs and PSA
levels in the media were quantified. (C-D) Western blots to measure AR-dependent
expression of PSA and FKBP51 were performed in LNCaP (C) and VCaP (D) cells.
Cells were treated with the indicated concentrations of MJC13 in the presence (C) or
absence (D) of DHT for 24 hrs, lysed, and lysates were electrophoresed and
immunoblotted for FKBP51, PSA and GAPDH (loading control). The upper panels show
representative Western blots. The lower panels represent averaged densitometry data
from at least 3 independent experiments. (E) left panel: PSA and TMPRSS2 gene
expression in LNCaP cells was assessed by Q-PCR. Cells were treated for 24 hours
with increasing concentrations of MJC13 in the presence of 10% fetal bovine serum.
Data are displayed as expression relative to that of 18S rRNA; right panel: R1881dependent and independent PSA gene expression in 22Rv1 cells was assessed by QPCR. Cells (in the presence of charcoal-stripped serum) were untreated, treated for 24
hours with MJC13 alone, or treated for 24 hours with 0.5 nM R1881 in the presence and
absence of 30 M MJC13. Data are displayed as PSA mRNA expression relative to that
of 18S rRNA. Each experiment was performed, at least, three times.
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Figure 4.3. MJC compounds Effectively Inhibit Androgen-Dependent Prostate
Cancer Cell Proliferation.
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Figure 4.3. MJC Compounds Effectively Inhibit Androgen-Dependent Prostate
Cancer Cell Proliferation. Tritium (tritiated thymidine) incorporation assays were
performed on LNCaP (A), LAPC4 (B), and 22Rv1 (C) cells treated with a range of
compound concentrations in the presence (closed symbols) or absence (open symbols)
of 0.5 nM DHT. The known AR antagonist bicalutamide (circles) was included for
comparison with MJC13 (squares). All data are expressed as a percentage with the
level of tritiated thymidine incorporation in the absence of compound for each condition
set to 100%.
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CHAPTER 5
DISCUSSION
Previous studies have shown that Hsp90-receptor complexes assembled from
purified components in vitro have abnormal compositions, lack dynamics, and fail to
dissociate upon hormone binding due to the active nature by which the receptors
achieve their hormone-bound conformations to which FKBP52 associates. Also
because of this dynamic process, these receptors are unstable in the absence of Hsp90
and difficult to purify in vitro. Consequently, it is impractical to use a simple purified
protein system to assess direct interactions between FKBP52 and its receptors. Any
potential interactions between FKBP52 and the receptors would occur within the context
of the Hsp90 complex given that FKBP52-mediated potentiation of receptor function
requires FKBP52 binding to Hsp90 [25].
Functional domain mapping approaches in yeast suggested that the FKBP52
FK1 domain, the proline-rich loop overhanging the PPIase catalytic pocket, is critical for
regulation of receptor function through interaction with the receptor hormone binding
domain [101]. In support of this idea we have identified a surface region on the AR
hormone binding domain that displays increased dependence on FKBP52 for normal
function when mutated (also termed FKBP52 hypersensitivity) (Figure 2.6). This surface
directly correlates with the recently identified BF3 surface. Although we do not provide
direct evidence for FKBP52 interaction with BF3, the data presented here indicate, that
FKBP52 can indirectly influence receptor function through this surface. In addition, we
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demonstrate that FKBP52 regulation of receptor function can be blocked by small
molecules that are predicted to bind the BF3 surface.
In this dissertation we studied the role of the FKBP52 immunophilin in AR action
by measuring the effects FKBP52-specific inhibitors have in AR-mediated processes
such as receptor nuclear translocation and prostate cancer cells proliferation. We
demonstrated that the lead molecules, MJC13 and MJC01, specifically inhibited
FKBP52-enhanced receptor activity in both yeast and mammalian cell lines (Figures 2.4
and 2.7). MJC13 prevented hormone-induced receptor-Hsp90 complex dissociation in
the presence of FKBP52, which resulted in less receptor translocation to the nucleus
(Figure 3.3). As a consequence AR-dependent gene expression and cell proliferation in
cellular models of prostate cancer were inhibited (Figure 4.2). Taken together, these
data suggest that FKBP52 regulates AR function through the BF3 surface and that
FKBP52-mediated receptor potentiation can be inhibited by targeting the BF3 surface
with small molecules.
Even though our data suggest that MJC13 binds the AR BF3 surface, efforts to
provide direct evidence of this interaction through SPR analysis and co-crystalization
have not been instructive. These difficulties are not unique among molecules known or
thought to bind the BF3 region since providing direct evidence of BF3 binding for some
of the fenamic acid-derived AR inhibitors have also proven difficult. In addition, some of
these molecules bind weakly to BF3, therefore we postulate that these molecules might
associate weakly with multiple sites on the receptor hormone binding domain at high
concentrations. It is also possible that the BF3 surface on the purified AR hormone
binding domain is not in an optimal conformation for MJC13 binding in the absence of
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the chaperone proteins that actively assist with the receptor folding. Despite these
difficulties, multiple lines of evidence suggest that MJC13 inhibits FKBP52-mediated AR
function through binding BF3.
We also demonstrated that FKBP52 can influence at least a portion of the BF3
surface (Figure 2.6), and molecules that specifically inhibit FKBP52 regulation of
receptor function are structurally similar to known BF3 binding molecules. In addition,
many of the compounds tested in the SAR studies differentially affected AR-P723S as
compared to wild type AR and some of the molecules inhibitory action was specific for
AR-P723S (Figure 2.3). Thus, mutations within the putative BF3 binding surface
accentuate inhibitor activity. Finally, MJC13 effectively blocked hormone-dependent
PSA expression but failed to block hormone-insensitive PSA expression in 22Rv1 cells
(Figure 4.2). Given that MJC13 is predicted to target the BF3 surface of the AR LBD,
MJC13 would not be expected to affect the expression of PSA in these cells that results
from a constitutively active AR protein lacking the LBD. As a final point, in silico docking
simulations support the idea that MJC13 binds BF3 (Figure 3.2). Taken together these
data suggest that MJC13 binds the BF3 surface. However, in the absence of direct
evidence, we must consider the possibility that MJC13 and its derivatives do not bind
AR. This possibility does not make the data and the compounds presented here any
less significant since their inhibitory effect is specifically for FKBP52-enhanced receptor
function.
Although elucidating the structural components that confer FKBP52-specificity is
of importance for understanding FKBP52 function, compounds that generally inhibit
receptor in the absence of FKBP52 are no less interesting from a therapeutic
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perspective. However, the most potent compounds identified in these studies, MJC01
and MJC13, were more specific for FKBP52-regulated receptor activity, which may
reflect the receptor’s requirement for FKBP52 at low hormone concentrations. Based on
available evidence it is logical to assume that at physiological concentrations in vivo AR
dependence on the presence of FKBP52 is heightened, especially in the case of
hormone refractory prostate cancer. Thus, compounds that target the regulation of AR
by FKBP52 may display increased potency in these settings and represent attractive
therapeutic candidates for the treatment of prostate cancer.
Conversely, FKBP52 is not a specific regulator of AR, but also regulates GR and
PR [25, 26, 33]. Therefore, pharmacological inhibition of FKBP52 would lead to the
inhibition of activity from all three receptors. However, MJC13 and its derivatives are
proposed to associate with the FKBP52 regulatory site on the receptor hormone binding
domain, which provides an opportunity for receptor-specific targeting of FKBP52
regulation. We showed that FKBP52 inhibitors have distinct effects depending upon
which receptor was being analyzed. Although none of the compounds we tested
displayed complete AR specificity, many of them, including MJC13 (Figures 2.2 and
2.3), were more potent inhibitors of AR as compared to GR. This data suggests that the
design of receptor-specific FKBP52 inhibitors may be possible. Further studies to
characterize and specifically target analogous surfaces on other steroid hormone
receptors are necessary. Nevertheless, given the role of FKBP52 in other nuclear
receptor signaling these compounds also show promise for the treatment of hormone
related diseases, male contraception, and research reagents for the study of steroid
hormone receptor interactions and function.
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In summary, we have identified a surface region on the AR hormone binding
domain that, when mutated, displays a greater dependence on FKBP52 for normal
function. This surface directly correlates with the recently characterized BF3 surface. In
addition, we have developed a series of small molecules that specifically inhibit FKBP52
regulation and enhancement of AR function. These small molecules are predicted to
mediate their effects through binding BF3, a surface that we propose to be the FKBP52
interaction and/or regulatory surface on AR. The most promising compound, MJC13,
inhibits hormone-dependent AR-Hsp90 complex dissociation and effectively blocks ARdependent gene expression in cellular models of prostate cancer at low micromolar
concentrations.
Further studies to characterize the MJC13 target sight, improve compound
efficacy, and improve receptor specificity are needed. MJC13 is the first example of an
inhibitor that specifically targets the regulation of receptor function by an Hsp90associated cochaperone and serves as an excellent starting point for the development
of FKBP52-specific compounds for the treatment of hormone-dependent diseases such
as prostate cancer. Although we do not know the exact mechanism of action of the
inhibitory molecules, we can conclude that AR signaling is targeted through FKBP52.
Further understanding of the mechanism involve in FKBP52 inhibition and the role this
immunophilin protein has in prostate cancer development, tumor formation and
progression will require more advance approaches such as in mouse models of prostate
cancer.
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APPENDIX

Yeast strains used in these studies.

Yeast
Strain

Receptor

Immunophilin
Protein

Reporter
Plasmid

Growing Media

1553

WT AR

None

β-gal

Synthetic complete media
minus leucine, uracil and
tryptophan (SC-LUW)

1555

WT AR

FKBP52

β-gal

Synthetic complete media
minus leucine, uracil and
tryptophan (SC-LUW)

β-gal

Synthetic complete media
minus leucine, uracil and
histidine (SC-LUH)

1483

WT AR

None

1496

AR-P723S

FKBP52

β-gal

Synthetic complete media
minus leucine, uracil and
histidine (SC-LUH)

1347

GR

None

β-gal

Synthetic complete media
minus uracil, histidine and
tryptophan (SC-UHW)

β-gal

Synthetic complete media
minus uracil, histidine and
tryptophan (SC-UHW)

1345

GR

FKBP52
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